D. Boral Capital Reiterates “Buy” Rating for Checkpoint Therapeutics (NASDAQ:CKPT)

D. Boral Capital reiterated their buy rating on shares of Checkpoint Therapeutics (NASDAQ:CKPT) in a report released on Monday morning,Benzinga reports. The brokerage currently has a $4.80 price target on the stock, down from their previous price target of $9.00.

Several other analysts have also recently issued reports on CKPT. Lake Street Capital boosted their price objective on shares of Checkpoint Therapeutics from $4.00 to $7.00 and gave the company a “buy” rating in a research note on Monday, December 16th. HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of Checkpoint Therapeutics in a report on Monday, December 16th.

Checkpoint Therapeutics Stock Performance

CKPT opened at $3.98 on Monday. Checkpoint Therapeutics has a 1 year low of $1.38 and a 1 year high of $4.50. The company’s 50 day simple moving average is $3.10 and its 200 day simple moving average is $3.08. The stock has a market capitalization of $194.36 million, a PE ratio of -2.16 and a beta of 1.41.

Insider Activity at Checkpoint Therapeutics

In other news, CFO William Garrett Gray sold 74,110 shares of the company’s stock in a transaction dated Thursday, February 6th. The stock was sold at an average price of $3.67, for a total value of $271,983.70. Following the completion of the sale, the chief financial officer now owns 1,458,644 shares of the company’s stock, valued at $5,353,223.48. This represents a 4.84 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO James F. Oliviero III sold 10,331 shares of the stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $3.15, for a total value of $32,542.65. Following the completion of the sale, the chief executive officer now owns 3,775,019 shares of the company’s stock, valued at approximately $11,891,309.85. This trade represents a 0.27 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 582,336 shares of company stock worth $2,156,801. Company insiders own 2.10% of the company’s stock.

Hedge Funds Weigh In On Checkpoint Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Ameriflex Group Inc. acquired a new stake in Checkpoint Therapeutics in the fourth quarter valued at approximately $32,000. Squarepoint Ops LLC purchased a new position in shares of Checkpoint Therapeutics in the fourth quarter valued at $230,000. Two Sigma Investments LP boosted its stake in shares of Checkpoint Therapeutics by 73.8% in the fourth quarter. Two Sigma Investments LP now owns 73,032 shares of the company’s stock valued at $234,000 after purchasing an additional 31,002 shares during the period. Man Group plc acquired a new stake in Checkpoint Therapeutics during the 4th quarter valued at $35,000. Finally, OMERS ADMINISTRATION Corp purchased a new stake in Checkpoint Therapeutics during the 4th quarter worth $374,000. 22.00% of the stock is owned by institutional investors and hedge funds.

Checkpoint Therapeutics Company Profile

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.